Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan H Fox

Showing results (121-130 of 178) with videos related to

Pageof 18
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|September 18, 2015
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PETYilong Ma, Tom H Johnston, Shichun Peng, et al.
Archives of Neurology|February 14, 2007
Factors associated with dopaminergic drug-related pathological gambling in Parkinson diseaseValerie Voon, Teri Thomsen, Janis M Miyasaki, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 25, 2011
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's diseaseSusan H Fox, Regina Katzenschlager, Shen-Yang Lim, et al.
Neuropharmacology|January 23, 2014
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmosetPhilippe Huot, Tom H Johnston, Katie D Lewis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 31, 2003
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's diseaseJuha-Matti Savola, Michael Hill, Mia Engstrom, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 13, 2011
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-timePhilippe Huot, Tom H Johnston, Katie D Lewis, et al.
Annals of Neurology|October 26, 2018
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving conceptsAlberto J Espay, Francesca Morgante, Aristide Merola, et al.
Neuropharmacology|December 4, 2017
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's diseaseTom H Johnston, Eboo Versi, Patrick A Howson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's diseaseSusan H Fox, Leonard Verhagen Metman, John G Nutt, et al.
Parkinsonism & Related Disorders|January 30, 2019
Diagnostic delay in Parkinson's disease caused by PRKN mutationsMarta Ruiz-Lopez, Maria Eliza Freitas, Lais M Oliveira, et al.
Pageof 18

Showing results (121-130 of 178) with videos related to

Sort By:
Pageof 18
Movement Disorders : Official Journal of the Movement Disorder Society|September 18, 2015
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PETYilong Ma, Tom H Johnston, Shichun Peng, et al.
Archives of Neurology|February 14, 2007
Factors associated with dopaminergic drug-related pathological gambling in Parkinson diseaseValerie Voon, Teri Thomsen, Janis M Miyasaki, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 25, 2011
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's diseaseSusan H Fox, Regina Katzenschlager, Shen-Yang Lim, et al.
Neuropharmacology|January 23, 2014
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmosetPhilippe Huot, Tom H Johnston, Katie D Lewis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 31, 2003
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's diseaseJuha-Matti Savola, Michael Hill, Mia Engstrom, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 13, 2011
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-timePhilippe Huot, Tom H Johnston, Katie D Lewis, et al.
Annals of Neurology|October 26, 2018
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving conceptsAlberto J Espay, Francesca Morgante, Aristide Merola, et al.
Neuropharmacology|December 4, 2017
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's diseaseTom H Johnston, Eboo Versi, Patrick A Howson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 4, 2017
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's diseaseSusan H Fox, Leonard Verhagen Metman, John G Nutt, et al.
Parkinsonism & Related Disorders|January 30, 2019
Diagnostic delay in Parkinson's disease caused by PRKN mutationsMarta Ruiz-Lopez, Maria Eliza Freitas, Lais M Oliveira, et al.
Pageof 18